Non-insulin drugs in Diabetes Mellitus type 1 (Metformine, IDPP-4, Pramlintida, AGLP-1, ISGLT -2)
DOI:
https://doi.org/10.47196/diab.v53i2Sup.230Keywords:
drugs, diabetesAbstract
There are approximately 25 million patients with type 1 diabetes mellitus (DM1) in the world, a figure that would triple in 2050. Although the optimum is to reach A1c levels <7% to avoid and / or slow down the onset / evolution of chronic complications, only 30% of patients achieve this. Furthermore, carbohydrate (HD) count without adequate general dietary education, associated with intensified insulin therapy (IT), is nowadays linked to a higher incidence of hypoglycemia, obesity and other risk factors such as dyslipidemia (DSL), hypertension (HT), obesity (O) and abdominal obesity (OA) in this population, which generates a very frequent phenotype of patients with DM1 associated with metabolic syndrome (SM).
References
- Bode BW, et. al. Adjuntive therapy for type 1 diabetes. Endocr Pract 2016; 22 (2).
- Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38:971-978.
- National Institutes of Health. ClinicalTrials.gov. Disponible en: https://clinicaltrials.gov.
- Standl E, et al. Metformin in type 1 diabetes. The Lancet Diabetes & Endocrinology 2017; Vol 5, Issue 8: 567-569.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
